Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition

PURPOSE: Although durable responses can be achieved with tyrosine kinase inhibitors such as imatinib in melanomas harboring KIT mutations, the efficacy of alternative inhibitors after progression to imatinib and the activity of these agents on brain metastases is unknown. EXPERIMENTAL DESIGN: We con...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Clin Cancer Res
Egile Nagusiak: Carvajal, Richard D., Lawrence, Donald P., Weber, Jeffrey S., Gajewski, Thomas F., Gonzalez, Rene, Lutzky, Jose, O’Day, Steven J., Hamid, Omid, Wolchok, Jedd D., Chapman, Paul B., Sullivan, Ryan J., Teitcher, Jerrold B., Ramaiya, Nikhil, Giobbie-Hurder, Anita, Antonescu, Cristina R., Heinrich, Michael C., Bastian, Boris C., Corless, Christopher L., Fletcher, Jonathan A., Hodi, F. Stephen
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2015
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5013827/
https://ncbi.nlm.nih.gov/pubmed/25695690
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-14-1630
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak